Adam Friedman, CEO of the Scorpion Therapeutics spinout, said the deal helps both companies accelerate research "faster than either of us could alone."
An article from
Dive Brief
Adam Friedman, CEO of the Scorpion Therapeutics spinout, said the deal helps both companies accelerate research “faster than either of us could alone.”
Published June 25, 2026
General view of the Swiss pharmaceutical and drug company Novartis AG headquarters on April 11, 2025 in Basel, Switzerland.
Novartis, Antares Partner To Pursue Undruggable Cancer Targets In $1.9 Billion Deal - Novartis (NYSE:NVS)
Novartis taps Antares in small molecule discovery pact with $105M upfront
Zymeworks acquires struggling Theravance for $929M
A 5-month sprint: Behind Pfizer’s $10B deal and Innovent’s global pharma ambition
Fierce Pharma Asia—Historic solid tumor CAR-T nod; Inside Pfizer, Innovent’s $10B pact; More China deals
Antares inks Novartis collaboration worth up to $1.9 billion to develop therapies targeting hard-to-treat cancers.
Antares Therapeutics inks $105M upfront deal with Novartis to discover small molecules against undruggable cancer targets, with…
Swiss pharmaceutical giant Novartis is nearing a deal to buy biotechnology company Avidity Biosciences for more than $70 a share,…
Novartis on Thursday forecast sales growth of 5% to 6% per year to 2030, on a currency-adjusted basis, as sales for cancer drugs…
The Swiss pharma giant is betting on a next-generation allergy treatment that may prove to work faster and better than anything…
Novartis says acquisition US biotech company Avidity Biosciences will boost mid-term growth.
